Advertisement
CNMD vs NDRA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNMD is a Hold and NDRA is a Buy.
CNMD in upward trend: price rose above 50-day moving average on November 03, 2026
CNMD moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CNMD as a result. In 57 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for CNMD just turned positive on November 04, 2026. Looking at past instances where CNMD's MACD turned positive, the stock continued to rise in 32 of 47 cases over the following month. The odds of a continued upward trend are 68%.
The 10-day moving average for CNMD crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +15.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNMD advanced for three days, in 200 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The 10-day RSI Indicator for CNMD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In 14 of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 60 cases where CNMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
CNMD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CNMD entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CNMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.481) is normal, around the industry mean (4.142). P/E Ratio (27.838) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.016) settles around the average of (0.011) among similar stocks. P/S Ratio (1.055) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NDRA saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for NDRA moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 34 similar instances where the indicator exited the overbought zone. In 31 of the 34 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NDRA as a result. In 84 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NDRA turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NDRA moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NDRA crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NDRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NDRA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NDRA's RSI Oscillator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +3.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NDRA advanced for three days, in 184 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NDRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. NDRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.155) is normal, around the industry mean (67.298). P/E Ratio (-0.773) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NDRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
CNMD | NDRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 81 | 99 | |
PRICE GROWTH RATING 1..100 | 41 | 60 | |
P/E GROWTH RATING 1..100 | 14 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CNMD's Valuation (62) in the Medical Specialties industry is somewhat better than the same rating for NDRA (95) in the Biotechnology industry. This means that CNMD’s stock grew somewhat faster than NDRA’s over the last 12 months.
CNMD's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NDRA (100) in the Biotechnology industry. This means that CNMD’s stock grew similarly to NDRA’s over the last 12 months.
CNMD's SMR Rating (81) in the Medical Specialties industry is in the same range as NDRA (99) in the Biotechnology industry. This means that CNMD’s stock grew similarly to NDRA’s over the last 12 months.
CNMD's Price Growth Rating (41) in the Medical Specialties industry is in the same range as NDRA (60) in the Biotechnology industry. This means that CNMD’s stock grew similarly to NDRA’s over the last 12 months.
CNMD's P/E Growth Rating (14) in the Medical Specialties industry is significantly better than the same rating for NDRA (100) in the Biotechnology industry. This means that CNMD’s stock grew significantly faster than NDRA’s over the last 12 months.
| CNMD | NDRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 68% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 90% |
| Advances ODDS (%) | 11 days ago 68% | 11 days ago 81% |
| Declines ODDS (%) | 3 days ago 80% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 89% |
| Aroon ODDS (%) | 3 days ago 76% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CNMD’s FA Score shows that 1 FA rating(s) are green while NDRA’s FA Score has 0 green FA rating(s).
- CNMD’s FA Score: 1 green, 4 red.
- NDRA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CNMD’s TA Score shows that 5 TA indicator(s) are bullish while NDRA’s TA Score has 3 bullish TA indicator(s).
- CNMD’s TA Score: 5 bullish, 5 bearish.
- NDRA’s TA Score: 3 bullish, 7 bearish.
Price Growth
CNMD (@Medical/Nursing Services) experienced а -1.77% price change this week, while NDRA (@Medical Specialties) price change was -7.51% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.37%. For the same industry, the average monthly price growth was -4.49%, and the average quarterly price growth was -5.80%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.79%. For the same industry, the average monthly price growth was -7.29%, and the average quarterly price growth was +34.42%.
Reported Earning Dates
CNMD is expected to report earnings on Feb 03, 2027.
NDRA is expected to report earnings on Apr 01, 2027.
Industries' Descriptions
@Medical/Nursing Services (+1.37% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-1.79% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
CNMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNMD has been loosely correlated with NVST. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CNMD jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To CNMD | 1D Price Change % | ||
|---|---|---|---|---|
| CNMD | 100% | +0.22% | ||
| NVST - CNMD | 49% Loosely correlated | -0.69% | ||
| KIDS - CNMD | 49% Loosely correlated | -0.71% | ||
| IART - CNMD | 48% Loosely correlated | +0.35% | ||
| ENOV - CNMD | 47% Loosely correlated | +0.14% | ||
| ZBH - CNMD | 46% Loosely correlated | -1.29% | ||
More | ||||
NDRA and
Correlation & Price change
A.I.dvisor tells us that NDRA and GMED have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NDRA and GMED's prices will move in lockstep.
| Ticker / NAME | Correlation To NDRA | 1D Price Change % | ||
|---|---|---|---|---|
| NDRA | 100% | -2.92% | ||
| GMED - NDRA | 29% Poorly correlated | -0.22% | ||
| ICUI - NDRA | 24% Poorly correlated | +1.11% | ||
| CNMD - NDRA | 23% Poorly correlated | +0.22% | ||
| LAB - NDRA | 22% Poorly correlated | +8.60% | ||
| SGHT - NDRA | 21% Poorly correlated | -1.46% | ||
More | ||||